Wolfgang Jacob

Phase I study of emactuzumab single agent or in combination with paclitaxel in patients with advanced/metastatic solid tumors reveals depletion of immunosuppressive M2-like macrophages

C. Gomez-Roca, Antoîne Italiano, Christophe Le Tourneau et al. · Annals of Oncology · 2019 · 202 citations · Full text

Life Sciences, Immunology, Oncology +16

Anti-CSF-1R emactuzumab in combination with anti-PD-L1 atezolizumab in advanced solid tumor patients naïve or experienced for immune checkpoint blockade

Carlos Gomez‐Roca, Philippe A. Cassier, Dmitriy Zamarin et al. · Journal for ImmunoTherapy of Cancer · 2022 · 104 citations · Full text

Medicine, Oncology, Pharmacology +17

RG6234, a GPRC5DxCD3 T-Cell Engaging Bispecific Antibody, Is Highly Active in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Updated Intravenous (IV) and First Subcutaneous (SC) Results from a Phase I Dose-Escalation Study

Carmelo Carlo‐Stella, Rita Mazza, Salomon Manier et al. · Blood · 2022 · 90 citations

Medicine, Oncology, Pharmacotherapy +17

Phase Ib study evaluating safety and clinical activity of the anti-HER3 antibody lumretuzumab combined with the anti-HER2 antibody pertuzumab and paclitaxel in HER3-positive, HER2-low metastatic breast cancer

Andreas Schneeweiß, Tjoung‐Won Park‐Simon, Joan Albanell et al. · Investigational New Drugs · 2018 · 79 citations · Full text

Medicine, Oncology, Pharmacology +17

Phase Ib study of anti-CSF-1R antibody emactuzumab in combination with CD40 agonist selicrelumab in advanced solid tumor patients

Jean‐Pascal Machiels, Carlos Gomez‐Roca, Jean‐Marie Michot et al. · Journal for ImmunoTherapy of Cancer · 2020 · 78 citations · Full text

Pharmacy, Oncology, Pharmacology +17